Preclinical development of siRNA therapeutics for AL amyloidosis
Open Access
- 12 May 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 18 (12), 1150-1156
- https://doi.org/10.1038/gt.2011.69
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA moleculesExperimental Hematology, 2010
- Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's DiseaseMolecular Therapy, 2009
- Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chainHaematologica, 2009
- Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease PatientsCurrent Biology, 2009
- Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion diseaseProceedings of the National Academy of Sciences, 2008
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences, 2007
- Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosisBone Marrow Transplantation, 2007
- Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult miceJournal of Neurochemistry, 2007
- Knockdown of the bovine prion gene PRNP by RNA interference (RNAi) technologyBMC Biotechnology, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001